Header Logo

Connection

ERNESTINA MELICOFF-PORTILLO to Rituximab

Back to Details
This is a "connection" page, showing publications ERNESTINA MELICOFF-PORTILLO has written about Rituximab.
ERNESTINA MELICOFF-PORTILLO
Connection Strength
0.044
Rituximab
  1. CTOTC-08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients. Am J Transplant. 2022 01; 22(1):230-244.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.